Moderna Stock Price, News & Analysis

Moderna (Nasdaq: MRNA) announced new findings from in vitro studies showing that its COVID-19 Vaccine effectively produces neutralizing titers against various SARS-CoV-2 variants. Vaccination elicited neutralization against all tested variants, including Beta, Delta, and others. Although some variants showed reduced antibody response, overall effectiveness remains promising. Moderna is actively studying new variants and developing a multivalent booster candidate. The mRNA platform continues to support vaccine development initiatives to combat evolving strains of the virus.

Moderna (NASDAQ: MRNA) announces that Kate Cronin will join as Chief Brand Officer on July 12, 2021. She will be part of the Executive Committee, reporting to CEO Stéphane Bancel. Cronin, previously Global CEO at Ogilvy Health, brings extensive experience in brand strategy and marketing in the biopharmaceutical sector. She aims to enhance Moderna's brand and communicate its potential in mRNA therapeutics. Moderna continues to evolve, with a diverse pipeline and a strong commitment to advancing mRNA science in vaccines and therapeutics.

Moderna, Inc. (Nasdaq: MRNA) announced the European Commission's purchase of an additional 150 million doses of its COVID-19 vaccine, raising total commitments to 460 million doses. Deliveries of the updated vaccine are set to begin in 2022, pending regulatory approval. Initial Phase 2 study data revealed that a 50 µg booster dose significantly increased neutralizing antibodies against SARS-CoV-2 variants. Moderna continues to meet its EU delivery commitments for 2021, supported by its mRNA platform and expanded manufacturing capabilities.

Moderna (Nasdaq: MRNA) has significantly expanded its workforce in Massachusetts, increasing from approximately 830 to 1,500 employees between March 2020 and March 2021. The company has created over 650 new jobs at its Norwood manufacturing facility. Moderna received a tax incentive from the Massachusetts Life Sciences Center for its commitment to employ 155 new full-time staff until 2025. A recent expansion in Norwood will boost Moderna's COVID-19 vaccine production capacity by 50%, aiming for up to 3 billion doses by 2022.

Moderna (Nasdaq: MRNA) has announced a U.S. government purchase of an additional 200 million doses of its COVID-19 vaccine, bringing the total confirmed commitment to 500 million doses. Deliveries include 110 million doses in Q4 2021 and 90 million in Q1 2022. As of June 14, 2021, Moderna has supplied 217 million doses. CEO Stéphane Bancel emphasized the collaboration's importance for vaccination efforts, including potential boosters. The company has received various authorizations globally for its vaccine and continues research funded by the U.S. government.

Moderna (Nasdaq: MRNA) has partnered with Magenta Investments to distribute the Moderna COVID-19 Vaccine and updated variant booster candidates in the UAE for 2021 and 2022. This agreement aims to enhance vaccine access in the region as part of a global effort against the COVID-19 pandemic. The Moderna vaccine utilizes an mRNA platform and has received various emergency authorizations across numerous countries. Moderna's commitment to innovation in vaccine technology continues to drive its position in the biopharmaceutical industry.

Rafael Holdings, Inc. (NYSE: RFL) announced the appointment of three new members to its Board of Directors: Ameet Mallik, CEO; Shannon Thyme Klinger, Chief Legal Officer of Moderna; and Mark McCamish, CEO of IconOVir Bio. Chairman Howard Jonas expressed optimism, stating the new board members bring significant expertise to advance the company's oncology pipeline. Ameet Mallik highlighted the importance of their industry experience in maximizing the potential of their therapeutics.

Moderna (Nasdaq: MRNA) announced the appointment of Paul Burton, M.D., Ph.D., as Chief Medical Officer, effective July 6, 2021. He brings over 16 years of experience from Johnson & Johnson, where he led global medical affairs. CEO Stéphane Bancel emphasized Burton's expertise as crucial for Moderna's international expansion and innovation in mRNA therapeutics. Burton’s background includes extensive publication in peer-reviewed journals and a focus on leveraging data science in medical engagement. His hiring follows the departure of previous CMO Tal Zaks after six years of service.

Moderna (Nasdaq: MRNA) has submitted an authorization application to Swissmedic for its COVID-19 vaccine's use in adolescents. CEO Stéphane Bancel expressed optimism about the vaccine's efficacy, noting a 100% effectiveness rate in a Phase 2/3 study with nearly 2,500 participants. The vaccine's safety profile remained consistent with previous studies, with mild adverse events reported. Moderna is also pursuing regulatory approvals globally, as it aims to aid in controlling the COVID-19 pandemic.